Surgery and OncologySurgery and OncologyХирургия и онкология2949-5857Publishing House ABV Press9010.17650/2220-3478-2013-0-4-31-33REVIEWОБЗОРЫ ЛИТЕРАТУРЫOPTIMIZATION OF METASTATIC COLORECTAL CANCER TREATMENT WITH RAS MUTATIONSОПТИМИЗАЦИЯ ТЕРАПИИ МЕТАСТАТИЧЕСКОГО КОЛОРЕКТАЛЬНОГО РАКА ПРИ МУТАЦИЯХ RASBolotinaL. V.БолотинаЛ. В.
Russian Federation
lbolotina@yandex.ruP.A. Herzen Moscow Oncology Research Institute, Ministry of Health of RussiaФГБУ «Московский научно-исследовательский онкологический институт им. П.А. Герцена» Минздрава России271220132431330103201501032015Copyright ©; 2013, ABV-pressCopyright ©; 2013, АБВ-пресс2013ABV-pressАБВ-прессhttps://onco-surgery.info/jour/about/editorialPolicieshttps://onco-surgery.info/jour/article/view/90

Current knowledge concerning impact of certain mutations on targeted therapy efficacy underlines the necessity to perform genetical analysis in order to choose appropriate treatment. Panitumumab addition to 1st line metastatic colorectal cancer chemotherapy in patients with wild-type RAS allows to achieve median progression-free survival up to 13 months and median overall survival of 41,3 months.

С позиций современных знаний о роли мутаций определенных генов в эффективности таргетной терапии необходимо проведение генетических исследований с целью выбора препарата направленного действия. Добавление панитумумаба к химиотерапевтическому режиму FOLFOX6 в первой линии терапии метастатического колоректального рака у больных с диким типом RAS позволяет достичь медианы времени до прогрессирования 13 мес, а медианы общей продолжительности жизни 41,3 мес.

colorectal cancerRAS mutationpanitumumabколоректальный ракмутации RASпанитумумаб1. Parkin D.M., Bray F., Ferlay J. et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.Parkin D.M., Bray F., Ferlay J. et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.2. Чиссов В.И., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2012 г. М., 2013.Чиссов В.И., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2012 г. М., 2013.3. Benson A.B. 3rd, Arnoletti J.P., Bekaii-Saab T. Colon cancer. J Natl Compr Canc Netw 2011;9:1238–90.Benson A.B. 3rd, Arnoletti J.P., Bekaii-Saab T. Colon cancer. J Natl Compr Canc Netw 2011;9:1238–90.4. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5(5):341–54.Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5(5):341–54.5. Инструкция по применению препарата Вектибикс (Vectibix).Инструкция по применению препарата Вектибикс (Vectibix).6. ASCO Provisional Clinical Opinion Recommendations, 2008.ASCO Provisional Clinical Opinion Recommendations, 2008.7. Douillard J.Y., Siena S., Cassidy J. et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28:4697–705.Douillard J.Y., Siena S., Cassidy J. et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28:4697–705.8. De Roock W., Claes B., Bernasconi D. et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11(8):753–62.De Roock W., Claes B., Bernasconi D. et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11(8):753–62.9. Oliner K.S., Douillard J.-Y., Siena S. et al. Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab plus FOLFOX versus FOLFOX as first-line treatment for metastatic colorectal cancer. ASCO 2013 (Poster Discussion Session, Gastrointestinal (Colorectal) Cancer). J Clin Oncol 2013;31(suppl; abstr 3511).Oliner K.S., Douillard J.-Y., Siena S. et al. Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab plus FOLFOX versus FOLFOX as first-line treatment for metastatic colorectal cancer. ASCO 2013 (Poster Discussion Session, Gastrointestinal (Colorectal) Cancer). J Clin Oncol 2013;31(suppl; abstr 3511).10. Schwartzberg L.S., Fernando R., Karthaus M. et al. Analysis of KRAS/NRAS mutations in PEAK: A randomized phase 2 study of FOLFOX6 + panitumumab or bevacizumab as first-line treatment for wild type KRAS (exon 2) metastatic colorectal cancer. ASCO 2013 (General Poster Session, Gastrointestinal (Colorectal) Cancer). J Clin Oncol 2013;31(suppl; abstr 3631).Schwartzberg L.S., Fernando R., Karthaus M. et al. Analysis of KRAS/NRAS mutations in PEAK: A randomized phase 2 study of FOLFOX6 + panitumumab or bevacizumab as first-line treatment for wild type KRAS (exon 2) metastatic colorectal cancer. ASCO 2013 (General Poster Session, Gastrointestinal (Colorectal) Cancer). J Clin Oncol 2013;31(suppl; abstr 3631).